期刊
THROMBOSIS RESEARCH
卷 164, 期 -, 页码 S54-S61出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2018.01.017
关键词
Cancer; Hypercoagulability; Cancer prognosis; Biomarkers; Predictive factors; Fibrinogen; D-dimer; Thrombin generation; NETs; Microparticles
资金
- AIRC 5xMILLE from the Italian Association for Cancer Research (AIRC) [12237]
Malignant disease is characterized by a hemostatic imbalance, usually shifted towards a procoagulant direction, and a high incidence of thrombotic complications. The mechanisms of hemostasis that are critically involved in thrombosis are also implicated in tumor progression, angiogenesis, and metastatic spread. As there is a close relationship between cancer and the clotting system, circulating biomarkers of activation of various hemostasis compartments (i.e. coagulation, fibrinolysis, platelets, endothelium, and other blood cells) have been extensively studied to predict cancer outcomes along with predicting the thrombotic risk. In this review, we will summarize the results of published studies and will focus on ongoing research and future directions of clotting activation bioproducts as biomarkers of cancer disease and progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据